Your first 90 days
Your first 90 days on Fabhalta for IgA nephropathy
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Fabhalta is one of 2 IgA nephropathy drugs whose first fill waits on a vaccine rather than a blood test, and the only one taken as a pill. The label requires shots against 2 kinds of bacteria at least 2 weeks before the first dose, and the pharmacy checks that they happened. After that the routine is a capsule morning and evening, a card in your wallet, and one rule about fever. This page lays out those first 3 months from the FDA label, the REMS, Novartis's own support program and one insurer's written rules.
What has to happen before the first bottle ships
Fabhalta is a specialty drug under a REMS, so the first fill waits on 2 vaccines, a certified prescriber and an insurance approval, not on a pharmacy counter. These are the 5 things in the way, in order.
Two vaccines, at least 2 weeks before the first dose
Fabhalta blocks part of the complement system, which is what the body uses against encapsulated bacteria. The label requires vaccination against Streptococcus pneumoniae and Neisseria meningitidis, serogroups A, C, W, Y and B, at least 2 weeks before day 1. The schedule is the ACIP one for people on a complement inhibitor. Having had these shots before may not be enough, because the schedule for complement inhibitors differs from the standard one.FDA label
Or antibiotics, if treatment cannot wait
If the nephrologist decides Fabhalta must start before the 2 weeks are up, the label says to give antibacterial prophylaxis and the vaccines as soon as possible. The REMS requires the prescriber to write that antibiotic prescription in that case.FDA label
A certified prescriber, and the counseling the REMS requires
Your nephrologist must be enrolled in the FABHALTA REMS. The REMS requires them to counsel you on the infection risk, give you the written materials, check your vaccination status, and hand you the Patient Safety Card. There is no patient enrollment form to sign for this REMS. Novartis lists a REMS helpline at 1-866-201-3101, 8 AM to 4 PM Eastern.FDA label
Novartis Patient Support, and the insurance approval
Most plans require prior authorization. Enrolling in Novartis Patient Support gives you one named team member, a welcome kit, and help locating and tracking the vaccines. For commercial insurance it also supplies free Fabhalta for up to 12 months while the plan decides, as long as the authorization or an appeal is filed within 45 days. Novartis also offers in-home vaccination by a licensed clinician at no cost for eligible patients.Novartis Patient Support
The pharmacy's check
Only pharmacies certified in the REMS can dispense Fabhalta, and Novartis routes prescriptions to a small network of specialty pharmacies. Before the first fill the pharmacy must confirm the prescriber is certified and contact the office to document your vaccination status or the antibiotic plan. It keeps checking for up to 6 months if you were not up to date at the start.FDA REMS review
The days that matter
Counted from the first dose, with the vaccine deadline 2 weeks before it, the refill every 30 days, and the Safety Card that outlasts the last dose. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Vaccines done, or scheduled
The pneumococcal and meningococcal shots need at least 14 days before day 1 to count. Novartis can send a clinician to give them at home. The office records the dates for the pharmacy.
Prior authorization, pharmacy check, delivery call
The pharmacy confirms the prescriber's REMS certification, documents the vaccine dates with the office, and calls you to arrange delivery. If the plan is slow, the Novartis bridge supply covers the gap.
First dose, 1 capsule, then another that evening
One 200mg capsule twice a day, swallowed whole, with or without food. Put the Patient Safety Card in your wallet the same day. A bottle holds 60 capsules, a 30-day supply.
Two weeks in
Abdominal pain, dizziness and nausea were the side effects that stood out in the IgAN trial, all mild or moderate. This is a reasonable point to note what has changed and tell the office, and to confirm the first refill is scheduled.
Refill, then every 30 days
A 60-capsule bottle runs out here. The pharmacy arranges delivery by phone, and in the first 6 months it may still be documenting your vaccination status with the office.
Refill, number 2
Lipid check and the first 3-month review
The label says Fabhalta can raise cholesterol and triglycerides and asks prescribers to check lipids periodically and treat if needed. Three months in is when many offices do the first one, alongside the protein and kidney function tests they already run.
Refill, number 3
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Fabhalta label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated July 16, 2026, read from the FDA's label database today. FDA label
- July 2026
Full approval for IgA nephropathy. The use changed from reducing protein in the urine in people with a protein ratio of 1.5g/g or more to slowing kidney function decline in adults at risk of progression. The 1.5g/g bar left the label. Insurer policies written before this still quote it.FDA letter
- March 2025
Complement 3 glomerulopathy was added as a third use, to reduce protein in the urine. The IgAN dose and rules did not change.FDA letter
- August 2024
Accelerated approval for IgA nephropathy, to reduce protein in the urine in adults at risk of rapid progression, with a required trial to confirm the benefit. The REMS Patient Guide was updated to say that earlier vaccinations may not be enough before starting.FDA letter
- March 2024
The Hib vaccine requirement was removed after an FDA letter to the complement inhibitor class, leaving pneumococcal and meningococcal vaccination.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Twice a day, whole, with or without food
The label says 200mg twice daily, swallowed whole, never opened, broken or chewed. Food does not matter.FDA label
- If you miss a dose
The Medication Guide says to take 1 dose as soon as you remember, even if it is almost time for the next one, then go back to the regular schedule. Two doses close together are allowed under this rule, which makes Fabhalta unusual.FDA label
- Fever is a call, not a wait
The Medication Guide lists fever with chills, headache with fever or a stiff neck, fever with a rash, confusion, fast breathing and eyes sensitive to light as signs of a serious infection. It says to get medical care right away. Show the Patient Safety Card to whoever treats you.FDA label
- The card outlasts the drug
The label requires carrying the Patient Safety Card at all times during treatment and for 2 weeks after the last dose. The infection risk continues for a few weeks after stopping.FDA label
- Medicines that change the dose
Strong CYP2C8 inhibitors such as gemfibrozil are not recommended with Fabhalta, and CYP2C8 inducers such as rifampin can make it stop working. Tell the pharmacist about every medicine, including antibiotics prescribed by someone else.FDA label
- Boosters
The label says to revaccinate on the ACIP schedule for as long as treatment lasts. Novartis Patient Support tracks the booster dates and its copay program covers up to $1,000 a year of vaccine costs for commercial insurance.FDA label
- Pregnancy and liver problems
The label says the data in pregnancy are not enough to know the risk and leaves the decision to a benefit and risk assessment with the prescriber. It does not recommend Fabhalta in severe liver impairment. Tell the nephrologist about either before day 1.FDA label
- Storage
Room temperature, 68 to 77 degrees. The bottle has a child-resistant cap.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs the label ties to serious infection
Fever of any kind, with or without chills, chest pain and cough, a fast heartbeat, headache with nausea or a stiff neck, confusion, clammy skin, a rash, fast breathing, body aches, or light hurting the eyes. The Medication Guide says these can become life-threatening quickly. Get medical care at once, card in hand.FDA label
Stomach pain, dizziness and nausea
In the APPLAUSE-IgAN trial, abdominal pain occurred in 8% of patients on Fabhalta against 4% on placebo, and dizziness in 5% against 2%. Nausea was 4% against 1%, and all were mild or moderate. Serious encapsulated bacterial infections occurred in 3 of 259 patients on Fabhalta and none on placebo.FDA label
Cholesterol
The label reports higher total cholesterol, LDL and triglycerides in the PNH trials and asks prescribers to check lipids during treatment. This shows up on a blood test, not as a symptom, which is why the lipid check is on the timeline.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- The pharmacy cannot document the vaccinesThe REMS requires the pharmacy to confirm your vaccination status or the antibiotic plan with the prescriber before the first fill. The fix is the office sending the vaccine dates, or the prescriber writing the antibiotic prescription. The FDA's REMS rules let the pharmacy dispense and keep following up rather than hold the drug, so a long delay here is worth a call.FDA REMS review
- The prescription went to a pharmacy outside the networkOnly REMS-certified pharmacies dispense Fabhalta, through the small network Novartis uses. The prescriber's office resends it. This is a routing problem, not a denial.Novartis Patient Support
- Prior authorization pending or deniedPlans ask for the criteria below, most often the biopsy, a protein measurement, an ACE inhibitor or ARB at full dose, and proof of the vaccines and REMS enrollment. For commercial insurance the Novartis bridge supplies Fabhalta free for up to 12 months while the authorization or appeal is pending, if it is filed within 45 days of enrolling.Novartis Patient Support
- The vaccines themselves cost moneyNovartis's copay program covers up to $1,000 a year of vaccine costs for commercial insurance. Its Vaccination Support program gives the shots at home at no cost for eligible patients regardless of insurance.Novartis Patient Support
- A copay you cannot payCommercial insurance: the Co-Pay Plus program, as little as $0 up to $20,000 a year. Medicare, Medicaid, TRICARE and VA: the program's terms exclude you, and Novartis points to its Patient Assistance Foundation at 1-800-277-2254. Our help paying page lists the charity funds that are open.Novartis Patient Support
Blue Cross Blue Shield Federal Employee Program prior authorization policy, April 1, 2026
- Age 18 or older, with IgA nephropathy confirmed by kidney biopsy
- A urine protein-to-creatinine ratio of 1.5g/g or higher
- Taken with the highest recommended or tolerated dose of an ACE inhibitor or an ARB
- Kidney function (eGFR) of 20 or higher
- Prescribed by or on the advice of a nephrologist
- Vaccinated against pneumococcus, meningococcus and Hib at least 2 weeks before starting, unless treatment cannot be delayed
- The prescriber is enrolled in the Fabhalta REMS
Approval length. A year at a time, renewed if the urine protein ratio has fallen and the ACE inhibitor or ARB continues, with a limit of 400mg a day.
This policy was reviewed in March 2026, before the FDA's July 2026 full approval removed the 1.5g/g protein bar from the label. A newer version may set a lower threshold. It also still lists the Hib vaccine, which the FDA dropped from the label in March 2024. It is here as an example of what a plan asks for, not as a rule. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- One named team member from the start, a welcome kit, and help locating and tracking the vaccines and boosters
- Co-Pay Plus for commercial insurance, as little as $0 for Fabhalta up to $20,000 a year plus up to $1,000 a year toward the vaccines, not valid under Medicare, Medicaid, TRICARE or VA
- Free Fabhalta for up to 12 months while a commercial plan decides, if the prior authorization or appeal is filed within 45 days of enrolling
- In-home vaccination by a licensed clinician at no cost for eligible patients, whatever the insurance
- Home delivery through the specialty pharmacy, which calls to arrange each shipment
Trial Friend takes no money from this program. Novartis Patient Support
Five questions for the pharmacist or the support line
- Have you documented my vaccine dates with my nephrologist's office, and is anything still missing before you can ship?
- Which specialty pharmacy are you, and what number will the delivery call come from?
- I take these other medicines. Are any of them CYP2C8 inhibitors or inducers?
- If I get a fever at night, who do I call first, and what do I tell them about the card?
- When is my meningococcal booster due, and does Novartis or my plan pay for it?
Questions people ask in the first weeks
How long does it take to get Fabhalta after it is prescribed?
The vaccines set the floor: at least 2 weeks between the shots and the first dose, by the label, unless the nephrologist starts you on antibiotics instead. The prior authorization and the pharmacy's REMS check run alongside. Novartis's bridge supply exists because the insurance step is often slower than the vaccines.
Do I have to get vaccinated before Fabhalta?
Yes, by the label, against Streptococcus pneumoniae and Neisseria meningitidis on the ACIP schedule for complement inhibitors, at least 2 weeks before the first dose. Earlier shots may not count because that schedule differs from the standard one. If treatment cannot wait, the label says to start antibiotics and vaccinate as soon as possible.
Can I pick up Fabhalta at my regular pharmacy?
No. Only pharmacies certified in the FABHALTA REMS can dispense it, and Novartis routes prescriptions to a small network of specialty pharmacies that deliver to your home.
What if I miss a dose of Fabhalta?
Take 1 dose as soon as you remember, even if the next one is close, then continue on the usual schedule. That is the Medication Guide's wording.
What is the Patient Safety Card?
A card from your prescriber that says you take a complement inhibitor, lists the signs of serious infection, and tells any doctor treating you to contact your prescriber. The label requires carrying it at all times during treatment and for 2 weeks after the last dose.
Why was Fabhalta denied by my insurance?
Most often the plan wants the biopsy, a protein level above its threshold, an ACE inhibitor or ARB at full dose, or proof of the vaccines and REMS enrollment. Older policies still quote the 1.5g/g protein bar that the July 2026 label dropped, so the appeal may be about that. The nephrologist's records usually resolve it.
Does Fabhalta require blood tests?
No scheduled test is written into the label the way a liver test is for some drugs. The label does ask prescribers to check cholesterol and triglycerides during treatment, and the nephrologist keeps tracking protein and kidney function to see whether it is working.
Free email alert
Hear when the Fabhalta label changes
One email the day the FDA revises the Fabhalta label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Fabhalta only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow IgA nephropathy for new trials, FDA decisions and label changes for every treatment.
Sources
- FABHALTA (iptacopan) prescribing information and Medication Guide, revised July 2026, Novartis, via openFDA and DailyMed, July 16, 2026.
- NDA 218276 REMS review, outpatient pharmacy requirements for FABHALTA, FDA, December 5, 2023.
- FABHALTA for IgAN, about Novartis Patient Support, Co-Pay Plus terms and Vaccination Support, Novartis, November 6, 2026.
- Pharmacy Policy 5.85.055, Fabhalta (iptacopan), Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
- NDA 218276/S-007 approval letter, IgAN full approval, FDA, July 16, 2026.
- NDA 218276/S-004 approval letter, C3G, FDA, March 20, 2025.
- NDA 218276/S-001 approval letter, IgAN accelerated approval, FDA, August 7, 2024.
- NDA 218276/S-002 approval letter, Hib vaccination removed, FDA, March 26, 2024.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing nephrologist. Found an error? Use the report link in the footer and it will be checked against the source.